{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Participants with ORR (CR + PR)"},{"measurements":[{"groupId":"OG000","value":"15"}],"title":"Participants without ORR (CR + PR)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"ORR = Compete Response (CR) + Partial Response (PR) by RECIST v 1.1 \\</= 24 weeks from the start of treatment","groups":[{"description":"Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. 16 participants will be accrued. If 2 or greater responses are seen, Stage 2 will accrue additional participants.\n\nZW25: ZW25 at 20mg/kg intravenously (IV) every two weeks.","id":"OG000","title":"Stage 1"},{"description":"If 2 or greater responses are seen during Stage 1, Stage 2 will accrue an additional 9 participants. Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy.\n\nZW25: ZW25 at 20mg/kg intravenously (IV) every two weeks.","id":"OG001","title":"Stage 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"No participants accrued to Stage 2 arm","reportingStatus":"POSTED","timeFrame":"</= 24 weeks from the start of treatment","title":"Overall Response Rate/ORR of Participants","type":"PRIMARY","unitOfMeasure":"Participants"}